Intellijoint Surgical Raises $11MM to Expand U.S. Launch of intellijoint HIP

Intellijoint Surgical Inc., a medical technology company that develops and commercializes 3D mini-optical navigation solutions for surgery, is excited to announce the completion of its Series A with $11MM in financing. The Series A was led by private investors from the Waterloo-Toronto corridor and closed in multiple tranches. Intellijoint is committed to improving patient outcomes through innovative technology made accessible for every patient, every surgeon and every healthcare facility.
 
“The U.S. launch of the next generation intellijoint HIP earlier this year is being extremely well received in the marketplace and is seeing significant growth,” commented Intellijoint Surgical CEO and Co-Founder, Armen Bakirtzian. “This Series A capital will allow Intellijoint to enhance its product offering with the Direct Anterior Approach Application and allow for expansion into new U.S. markets while enabling deeper penetration of Intellijoint’s presence in New York and Illinois.”
 
Intellijoint Surgical’s flagship product, intellijoint HIP, is a mini-optical navigation solution that assists orthopaedic surgeons in reaching preoperative surgical targets by providing real-time, intraoperative measurements for cup position, leg length, offset and hip center of rotation during a Total Hip Arthroplasty (THA). intellijoint HIP has been used in over 500 procedures in Canada and US, and is both Health Canada licensed and FDA approved.
 
“Intellijoint has addressed the shortcoming of traditional navigation. The miniature optical camera provides accurate measurements while compensating for patient movement, which is routine during a total hip replacement. It provides me with valuable information and I choose to use it in every case,” added Dr. Wayne Paprosky, Midwest Orthopaedics at Rush and member of Intellijoint’s scientific medical advisory board.